Different Volumes of Articaine for Inferior Alveolar Nerve Block in Irreversible Pulpitis

• Status: Recruiting
• Trial end date: 2023-10-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized clinical trial comparing the anaesthetic efficacy of 1.8 and 3.6 mL of Articaine for inferior alveolar nerve block when treating mandibular molars with Irreversible Pulpitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Armed Forces Institute of Dentistry, Pakistan
• Treatments: Carticaine; Epinephrine

Criteria

Inclusion Criteria:

• Healthy patients, including age group 18-55 years old

• Mandibular first molar tooth with symptomatic irreversible pulpitis

• Normal periapical radiographic appearance

• Moderate pain on Heft-Parker VAS ( > 54 mm and < 114 mm )

• Lingering pain or prolonged response to the cold testing (more than 10 seconds)

• Positive response to electric pulp testing

Exclusion Criteria:

• Patients who have taken analgesic or anti-inflammatory drugs within 6 hours before treatment visit

• History of allergy to 4% articaine or epinephrine

• Patients with systemic diseases

• Pregnant or lactating patients

• Teeth with severe periodontal disease

• Teeth with periapical radiolucency

• Any type of medication that could potentially interact with the anesthetic solution (antihypertensives)